Meral Gunaldi

Meral Gunaldi

Auto-generated profile, based on publicly available information

Meral Gunaldi

Bakirkoy Dr. Sadi Konuk Research and Training Hospital Department of Medical Oncology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2015 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MGMeral Gunaldi
Meral Gunaldi
BDBerna Bozkurt Duman
Berna Bozkurt Duman
CACigdem Afsar
Cigdem Afsar
SPSemra Paydas
Semra Paydas
MEMelek Erkisi
Melek Erkisi
BSBerksoy Sahin
Berksoy Sahin
Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic. The study was made up of 111 women with human epidermal growth factor receptor 2-overexpressing breast cancer who received trastuzumab in the Medical Oncology Department, between 2010 and 2013. A > 10% reduction of the baseline fraction of the left ventricular ejection fraction was observed in 18 (16.21%) women. Two individuals (1.8%) suffered from symptomatic heart failure, seven women showed cardiac symptoms and nine women showed asymptomatic decline of left ventricular ejection fraction. Risk factors for cardiotoxicity in the group included: postmenopausal status (p = 0.01), hypertension (p = 0.002), obesity (p = 0.0001), previously diagnosed coronary artery disease (p = 0.0001) and smoking (p = 0.03). The aforementioned factors pose a risk for cardiotoxicity. We found postmenopausal status, hypertension, obesity, previous coronary artery disease and smoking to be associated with an increased risk of cardiac dysfunction in women using trastuzumab. While administering trastuzumab to women who have these conditions, one must be aware of the risk of cardiotoxicity of trastuzumab.

1 December 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MGMeral Gunaldi
Meral Gunaldi
YOYildiz Okuturlar
Yildiz Okuturlar
AGAsuman Gedikbasi
Asuman Gedikbasi
CACevher Akarsu
Cevher Akarsu
MKMehmet Karabulut
Mehmet Karabulut
AKAlev Kural
Alev Kural

15 April 2015
Verified
Journal Article
Closed access
MGMeral Gunaldi
Meral Gunaldi
SGSema Goksu
Sema Goksu
DEDilek Erdem
Dilek Erdem
SGSeyda Gunduz
Seyda Gunduz
YOYildiz Okuturlar
Yildiz Okuturlar
MYMustafa Yildirim
Mustafa Yildirim

8 November 2016 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MGMeral Gunaldi
Meral Gunaldi
DEDilek Erdem
Dilek Erdem
SGSema Goksu
Sema Goksu
SGSeyda Gunduz
Seyda Gunduz
YOYildiz Okuturlar
Yildiz Okuturlar
MYMustafa Yildirim
Mustafa Yildirim

6 February 2011 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
BDBerna Bozkurt Duman
Berna Bozkurt Duman
IKIsmail Oğuz Kara
Ismail Oğuz Kara
MGMeral Günaldi
Meral Günaldi
VEVehbi Ercolak
Vehbi Ercolak

27 April 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MGMeral Günaldi
Meral Günaldi
CACigdem Afsar
Cigdem Afsar
BDBerna Bozkurt Duman
Berna Bozkurt Duman
IKIsmail Oguz Kara
Ismail Oguz Kara
UTUfuk Tatli
Ufuk Tatli
BSBerksoy Sahi̇n
Berksoy Sahi̇n
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.